TNFRSF18 and neoplasm: BALB/c mice with s.c. established 4 T1 tumors (4-6 mm in diameter) wereinjected i.t. with anti-PD-1/GITR mAb, cisplatin, paclitaxel or a combination of mAband cisplatin or paclitaxel, using the same dose/schedule as in the ID8 experiment.As shown in Figure 5B and 5C, combinedanti-PD-1/GITR mAb exhibited a similar antitumor effect in this model with evidentprolongation of overall survival (median survival 43 vs 25 days, p < 0.05 comparedwith control), however, all mice succumbed to tumor growth and died by 60 days aftertumor challenge.